AllDocs -> cancers

Case Statement Lung Cancer Australia Page 2 © The Australian Lung Foundation 2003 THE AUSTRALIAN LUNG FOUNDA TION We are pleased to present to you the Australian Lung Foundation's Case Statement on Lung Cancer in Australia. Lung cancer is the leading cause of cancer death. The number of cases has been steadily rising and more than 7,000 Australian men and women have been diagnosed with the disease each year since 1990. The number of men affected by lung cancer appears to have plateaued but women are increasingly diagnosed with the disease. Survival rates five years after diagnosis are less than 15%. Tobacco smoking causes the vast majority of lung cancers. Both current smokers and former smokers are at risk. Many of those who are currently being diagnosed with lung cancer began smoking ...

1 The Centers for Disease Control and Prevention (CDC) recently examined trends in mortality rates for the four leading sites for cancer -related deaths: lung /bronchus, colon/ rectum, prostate, and breast. These four sites are associated with 53% of all cancer -related deaths in the United States. Using the National Vital Statistics System, the CDC calculated the trends in mortality rates among whites, blacks, American Indians and Alaska Natives (AI/AN), Asians and Pacific Islands (API), and Hispanics. They found that AI/AN rates for lung , colorectal, and breast cancers have increased. These same rates, with the exception of lung cancer in women, have decreased over the other racial/ ethnic groups. Lung and bronchus cancer was responsible for over a quarter of all cancer deaths ...

Epidem iol ogy EUROPEAN PROGRAMME FOR INTERVENTION EPIDEMIOLOGY TRAINING Veyrier-du-Lac, 28 September – 18 October 2003 Tobacco and lung cancer Exercise Source : Centers for Disease Control Atlanta, GA, USA Page 2 Tobacco and lung cancer , Page 2 of 11 Objectives This exercise uses the classic studies by Doll and Hill which demonstrated a relationship between smoking and lung cancer . After completing this exercise, the participant should be able to: 1. Discuss the elements of design and the advantages and disadvantages of case-control versus prospective cohort studies; 2. Discuss some of the biases which might have affected these studies; 3. Calculate and interpret a relative risk, rate difference, odds ratio, and attributable risk among the exposed; 4. Appreciate how the ...

Lung Cancer Stage IV Treatment– Ottawa CAN Factual information verified by author, February 2001 . Part I: Classification Lung Cancer Treatment – Ottawa CAN 1. Publication Information Title of Decision Aid Making Choices: Treatment of Stage IV Non-small Lung Cancer Copyright Holders © Evans, Fiset, & O’Connor, 1997 Contact Information Ottawa Health Decision Centre Ottawa Health Research Institute, Clinical Epidemiology Unit Ottawa Hospital - Civic Campus C401-1053 Carling Avenue, Ottawa, Ontario, K1Y 4E9, Canada E-mail: ohdec@ohri.ca Availability Limited Current Use Used in clinical practice. Distributed to all Ontario thoracic surgeons and respirologists 2. Developer Information Credentials V. Fiset RN, MScN, Sisters of Charity of Ottawa Health Service A. O’Connor, RN, ...

23 C HAPTER 3: L UNG C ANCER O VERVIEW INTRODUCTION Learning about lung cancer is an important part of preparing for the decisions you will be making about your treatment and aftercare. The more you know about lung cancer , the better position you will be in to make informed decisions and advocate for your own interests. This chapter provides an overview of lung cancer topics including: lung cancer risk factors, how lung cancer develops, grows, and spreads, and types of lung cancers. The information will help you understand other chapters in this book, and your health care providers’ recommendations for your care. WHAT IS LUNG CANCER ? Lung cancer develops when normal lung cells sustain genetic damage that eventually leads to uncontrolled cell proliferation ...

i W ITH E VERY B REATH : A L UNG C ANCER G UIDEBOOK Page 2 ii W ITH E VERY B REATH : A L UNG C ANCER G UIDEBOOK Tina M. St. John, M.D. Medical Illustrations by Nucleus Medical Arts Cover Design by Stuart Blair Alliance for Lung Cancer Advocacy, Support, and Education ALCASE Page 3 iii W ITH E VERY B REATH : A L UNG C ANCER G UIDEBOOK Copyright © 2003 by Tina M. St. John, M.D. All rights reserved. No part of this book may be used ...

lung cancer Chemoprevention of lung cancer : from concept to reality van Zandwijk N Among all cancer , lung cancer is the leading cause of cancer death in the western world. The poor lung cancer survival figures argue powerfully for new approaches to control this disea se such as chemoprevention that has been defined as the use of agents that reverse, suppress or prevent lung carcinogenesis. Over 80% of lung cancers are attributed to tobacco and carcinogens from cigarette smoke form the unquestionable link between nicoti ne addiction and lung cancer . Confoundingly epidemiological studies show that not more than 15% of heavy smokers will ultimately develop lung cancer . The fact that 85% of heavy smokers will not develop lung cancer points to differences in susceptibility. D ietary and genetically determined factors seem to play an important role in modulating individual susceptibility ...

5 Chemoprevention of lung cancer : from concept to reality Roczniki Akademii Medycznej w Bialymstoku · Vol. 48, 2003 · Annales Academiae Medicae Bialostocensis ADDRESS FOR CORRESPONDENCE: Department of Thoracic Oncology Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam, The Netherlands e-mail: n.v.zandwijk@nki.nl tel.: 3120 5122958 fax: 31 20 5122752 Received 3.07.2003 Accepted 10.07.2003 Abstract Among all cancer , lung cancer is the leading cause of cancer death in the western world. The poor lung cancer survival figures argue powerfully for new approaches to control this disease such as chemoprevention, that has been defined as the use of agents that reverse, suppress or pre- vent lung carcinogenesis. Over 80% of lung cancers are attributed to tobacco and carcinogens from cigarette smoke ...

Nature 182 (1958 July 12), 108. 275 LUNG CANCER AND CIGARETTES T HE ASSOCIATION observable between the practice of cigarette-smoking an the incid- ence of cancer of the lung , to which attention has been actively, or even vehemently, directed by the Medical Research Council Statistical Unit, has been interpreted, by that Unit, almost as though it demonstrated a casuals connection between these variables. The suggestion 1 , among others that might be made on the present evidence, that without any direct causation being involved, both characteristics might be largely in- fluenced by a common cause, in this case the individual genotype, was indeed rejected by one writer 2 , although I believe that no one doubts the importance of the genotype in predisposing to cancers of all types. It seemed to me that although the importance of this ...

179 C HAPTER 9: L IVING WITH L UNG C ANCER INTRODUCTION A diagnosis of lung cancer can lead to many powerful feelings: shock, fear, denial, anger, anxiety, confusion, guilt, shame, uncertainty, loneliness, doubt, and others. These emotions are entirely normal responses to learning you have a life-threatening disease. Facing cancer is one of the most difficult challenges a person can experience. This chapter discusses the feelings and challenges you may have to deal with once you have been diagnosed with lung cancer . How you deal with these challenges depends on your coping style. Coping is broadly defined as a person’s way of dealing with difficult situations. Though the definition is broad, a person’s individual coping strategies are quite specific. However, no two people have identical coping strategies. ...

109 C HAPTER 6: T REATMENT FOR S MALL C ELL L UNG C ANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease. As you read this chapter, keep in mind that each person’s treatment plan is unique to his or her situation. This chapter provides information to help you discuss your treatment options with your cancer care team. However, it will not provide you with treatment recommendations. Many factors unique to your situation must be taken into account to make these crucial decisions. Only your cancer care team can make treatment recommendations. Ongoing clinical trials are evaluating how best to treat SCLC. This chapter presents current treatment standards at the time ...

74 C HAPTER 5: L UNG C ANCER T REATMENT O VERVIEW INTRODUCTION Lung cancer is currently treated with three forms of therapy: chemotherapy, radiation therapy, and surgery. They are used alone or in combination depending on the type of lung cancer and the stage of the disease. This chapter discusses basic concepts about each of these forms of therapy and their uses in the treatment of lung cancer . Chapters 6 and 7 review specific treatments for small cell and non-small cell lung cancer . Health care providers use specific language when discussing cancer treatment options. The beginning of this chapter explains many of the terms used. Familiarity with these medical terms will help you better understand your treatment options and make discussions with your health care providers ...

316 C HAPTER 12: N UTRITION AND L UNG C ANCER INTRODUCTION Lung cancer and its treatments place great energy demands on the body. Food is the body’s energy source. Adequate nutrition while living with lung cancer is very important, but can be challenging as some symptoms of lung cancer and side effects of treatment can interfere with eating and nutrition. This chapter reviews the basic principles of nutrition and gives tips on healthy eating for people living with lung cancer . The information can help you plan a diet that ensures your body is getting the energy and nutrients it needs. FOOD AND ENERGY The human body is always active. Even while you sleep, your body is working. The heart is beating, the lungs are breathing, the kidneys are filtering blood, old cells are being broken ...

472 L UNG C ANCER R ESOURCE D IRECTORY The Lung Cancer Resource Directory provides information about organizations, Internet sites, books, and other materials that may be useful to people living with lung cancer . Resources included in this section offer materials and services ALCASE and its clients have found useful. However, ALCASE is not responsible for your personal experience with the organizations or materials included. Certainly, other local and national resources are available that may be useful to people living with lung cancer beyond those included here. The exclusion of a particular resource should not be interpreted as a lack of endorsement. Use your judgment and consult with family members, friends, and professionals to determine the authenticity and legitimacy of all organizations that are new ...

Lung Cancer Therapeutic Market Expected to Reach $2.53 billion by 2007 For Immediate Release February 28, 2002 Contact: Rob Ellis Front Line Strategic Consulting, Inc. Phone: 650-525-1500 x123 Email: rob@frontlinesmc.com URL: www.frontlinesmc.com FOSTER CITY, CA – The worldwide market for lung cancer therapeutics is expected to reach $2.53 billion in 2007, due in part to the emergence of novel drug classes to treat small cell and non-small cell lung cancers. While the market as a whole will experience a 5.1% compound annual growth rate (CAGR), a great deal of share shifting will occur, according to Front Line’s new Strategic Market Report Lung Cancer Therapeutics, Emerging Trends and Opportunities. Lung cancer is the most prevalent cancer , affecting over three billion people worldwide in 2002. Non-small cell (NSCLC) is the most common lung cancer ...

315 Radiation Protection Dosimetry Vol. 104, No. 4, pp. 315–319 (2003) Published by Nuclear Technology Publishing 2003 US Government STUDIES OF RADON AND LUNG CANCER IN NORTH AMERICA AND CHINA J. H. Lubin Division of Cancer Epidemiology and Genetics, National Cancer Institute 6120 Executive Blvd, MSC-7244, Bethesda, MD 20892, USA INVITED PAPER Abstract — Studies of radon-exposed underground miners indicate that residential radon is the second leading cause of lung cancer . Seven case–control studies of residential radon have been conducted in North America and two in China, and represent all studies in these areas which included 200 or more lung cancer cases and used long-term radon detectors. North American studies enrolled 4081 cases and 5281 controls, and Chinese studies enrolled 1076 cases and 2015 controls. Based on analyses of pooled data, odds ...

lung cancer Modeling the Cell Carcinogenesis in Lung Cancer : Taking the Interaction Between Genetic Factors and Smoking into Account Li Deng and Marek Kimmel Department of Statistics Rice University Nov 13, 2003 Outline Some facts about lung cancer Brief review of several carcinogenesis models Two stage clonal expansion model Effects of smoking and genetic susceptibility on lung cancer development Some simulation results Discussion and further work Some facts on Lung Cancer Lung cancer has the leading mortality rate among all cancers in U.S. Strong correlation between cigarette consumption and lung cancer incidence (see the next page) About 85% lung cancer patients are smokers (former or current) About 10~15% of smokers develop lung ...

Stereotactic Lung Cancer Study Produces Positive Initial Results November 10, 2003 The initial phase of a clinical trial for treatment of early stage lung cancer has produced positive results, according to an article appearing Nov. 11 in the journal Chest. Researchers at Indiana University School of Medicine reported that the results of the extracranial stereotactic radioablation Phase I study for non-small cell lung cancer led the group to continue with the second phase of the clinical trial. The initial phase tested the toxicity of increasingly large doses of radiation precisely focused on the lung tumor. Enrollment in the trial began in February 2000 and 37 patients participated. Researchers report that surprisingly high doses of radiation were tolerated and 87 percent of patients had positive tumor response. Only six patients had local recurrence of cancer , all ...

What’s New in Lung Cancer Research? Source: American Cancer Society, November 2003 Lung cancer is the leading cause of cancer death in both men and women, and cigarette smoking is by far the most important risk factor for developing the disease. Right now, many researchers believe that prevention is the best way to fight lung cancer . Although nearly four decades have passed since studies revealed the link between smoking and lung cancers, scientists estimate that smoking is still responsible for about 85-90% of cases. Today’s research is continuing to look at: - Ways to help people quit smoking through counseling, nicotine replacement, and other medications - Ways to prevent young people from ever taking up smoking - Genetic factors that may make some people more likely to get lung cancer if they smoke or are exposed to secondhand smoke - Screening ...

Klaus Gottlieb Lung cancer staging - PET and Endoscopic Ultrasound Role of EUS-FNA in Mediastinal Lymphadenopathy: Can obviate the need for more invasive procedures such as mediastinoscopy, thoracoscopy, and thoracotomy Is cost-effective: Low cost and high yield. Especially useful if lymphadenopathy is present on CT but bronchoscopy negative. Complementary to PET scanning to rule out false positive results Limitations: Anterior mediastinum (air-filled trachea absorbs sound) Carcinoma of the lung remains among the leading causes of death in our region. For those with non-small cell lung cancer (large cell, squamous and adenocarcinoma), surgery remains the only hope for cure. Unfortunately, it is a hope that is too frequently shattered by the reality of unresectable disease at thoracotomy. The challenge is to identify those patients with N0, N1, or minimal N2 disease, ...

UNIVERSITY OF INSUBRIA BROWN UNIVERSITY VARESE-COMO International Conference Lung Cancer Screening and Early Diagnosis Five years after the 1998 Varese Conference Como, Italy Villa Olmo, Salone d’Onore November 8, 2003 Program Page 2 CONFERENCE OBJECTIVES 1. To consider whether existing evidence justifies a public policy change in support of population-based screening for lung cancer . 2. To address methodological, statistical, and biologic issues relevant to the question of how to best measure screening effectiveness in randomized early detection trials. 3. To critically evaluate existing data regarding benefits and problems associated with CT screening for lung cancer . 4. To present preliminary evidence suggesting that digital chest radiography ...

F ollowing a most cordial introduction by Conference Chairman Nevin Murray MD (British Columbia Cancer Agency) on behalf of the International Association for the Study of Lung Cancer (iaslc), a large audience, representing most of the 3200 participants enjoyed an impressive opening ceremony. Delegates from 77 countries attended. In addition to the over 140 invited speakers participating in Meet the Professor sessions, plenary sessions, interactive sessions and poster sessions, 307 presentations were selected from 1159 abstracts submitted; 600 posters, and 14 satellite symposia. The attendance greatly exceeded the 2000 attendees from 64 countries at the 9th International Congress held in Tokyo in 2000. The first international conference was held in Copenhagen 30 years ago with only a few hundred in attendance. Dr. Murray’s welcome was followed by a welcoming ...

October 30, 2003 International Early Lung Cancer Action Program: Protocol PI: Claudia I. Henschke, PhD, MD Weill Medical College of Cornell University New York, New York October 30, 2003 Overview . 1 Admissibility for collaboration . 1 Indications for screening 2 Regimen of screening.. 2 Image production Image reading Screening frequency Baseline screening Repeat screening Assessment of growth Biopsy Characterization of diagnosed cancers 7 Intervention policy 9 ELCAP Management System.. 9 Quality assurance.. 10 Outcome determination.. 11 Page 2 October 30, 2003 Overview The International Early Lung Cancer Action Program (I-ELCAP) has as its broad ...

Lung Cancer Management Study Day Aim To enable participants to have a general understanding of lung cancer epidemiology, diagnosis and treatment, including the social and psychosocial management. Learning Outcomes By the end of the day course participants will have: • An understanding of the incidence, risks and trends of lung cancer disease • A basic understanding of the clinical manifestations, tumour types and diagnostic methods used in lung cancer disease • Raised awareness of surgical procedures used in the management of lung cancer • A basic understanding of chemotherapy and radiotherapy in the treatment of lung cancer • Gained insight into the lung cancer issues arising through client personal experience . • An improved understanding of the manifestation, identification ...

Mayo Clin Proc, September 2003, Vol 78 CT Screening for Lung Cancer 1187 Mayo Clin Proc . 2003;78:1187-1188 1187 © 2003 Mayo Foundation for Medical Education and Research Commentary Computed Tomographic Screening for Lung Cancer : Home Run or Foul Ball? S TEPHEN J. S WENSEN , MD; J AMES R. J ETT , MD; D AVID E. M IDTHUN , MD; AND T HOMAS E. H ARTMAN , MD From the Department of Radiology (S.J.S., T.E.H.) and Division of Pulmonary and Critical Care Medicine and Internal Medicine (J.R.J., D.E.M.), Mayo Clinic, Rochester, Minn. This commentary was funded in part by the National Cancer Institute (RO1 CA 79935-03). Individual reprints of this article are not available. ...

Lung Cancer Research By Jolene Cheslock, MS, CCRP Research Coordinator St. Vincent Regional Cancer Center participates in lung cancer clinical trials that are conducted by the following National Cancer Institute (NCI) cooperative groups: Eastern Cooperative Oncology Group (ECOG) Radiation Therapy Oncology Group (RTOG) American College of Surgeons Oncology Group (ACOSOG) As a member of the Wisconsin Oncology Network (WON), St. Vincent Hospital participates in lung cancer clinical trials coordinated by the University of Wisconsin Comprehensive Cancer Center. St. Vincent also participates in some industry-funded studies for lung cancer . The following table lists the clinical trials currently available at St. Vincent for the treatment of lung cancer and the number of participants enrolled in 2002: Page 2 Study ...

1 Screening for Lung Cancer Edward J. Coleman, M.D. Lung cancer is the most common cause of cancer death in the United States as well as worldwide. In 2003, nearly 200,000 new cases of lung cancer will be identified in the United States and an estimated 165,000 lung cancer related deaths are expected to occur. Lung cancer survival is clearly related to stage at the time of diagnosis, with resected Stage I patients experiencing a 70-80% five-year survival. Screening studies have demonstrated that individuals identified with Stage I lung cancer and not undergoing resection have a 5-8% five-year survival. In order for a screening program to be effective, several criteria should be met. First, there should be a significant prevalence of the disease in the population. Second, there must be a significant advantage to detecting the disease at an earlier stage. ...

Platinum-containing chemotherapy has been commonly used as standard therapy for small cell lung cancer (SCLC). However, platinum causes renal dysfunction. 1,2 We report a SCLC patient with paraneoplastic nephrotic syndrome who was successfully treated with platinum-containing chemotherapy. A com- plete tumour response could be achieved; however, his proteinuria did not decrease and renal function got worse every time he re- ceived the chemotherapy. A 74-year-old male was admitted to our hospital with the oedema of the lower ex- tremities that developed during the last three months. On physical examination, oedema was still present. Laboratory results were as follows: haemoglobin 10.6 g/dl, potassium 4.3 mEq/l, serum creatinine 1.0 mg/dl, blood urea nitrogen 34.2 mg/dl. Creatinine clear- ance was 43.0 ml/min and the urine sediment was free of casts and ...

Eighty five percent of lung cancers in males and 77% in females are a direct result of smoking. Lung cancer is therefore one of the most preventable cancers. Non-smokers can also develop lung cancer as a result of passive smoking. This is when environmental tobacco smoke, (ETS), is inhaled. ETS is composed of both exhaled cigarette smoke and the smoke from the burning tip of a cigarette. It is estimated that 140 Australians die from lung cancer caused by passive smoking each year. Workers exposed to industrial substances such as nickel and chromium compounds and especially asbestos are also at risk of developing lung cancer . If the worker is also a smoker the risk is greatly increased. Diagnosis and treatment Several tests are available to confirm the presence of lung cancer . These include chest x- ray and CAT scan, examination ...